Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Surrozen (SRZN) Research & Development (2021 - 2025)

Surrozen (SRZN) has 5 years of Research & Development data on record, last reported at $7.8 million in Q3 2025.

  • For Q3 2025, Research & Development rose 49.5% year-over-year to $7.8 million; the TTM value through Sep 2025 reached $25.7 million, up 17.58%, while the annual FY2024 figure was $21.1 million, 22.39% down from the prior year.
  • Research & Development reached $7.8 million in Q3 2025 per SRZN's latest filing, up from $6.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $50.0 million in Q3 2021 and bottomed at $5.2 million in Q3 2024.
  • Average Research & Development over 5 years is $9.8 million, with a median of $7.8 million recorded in 2025.
  • Peak YoY movement for Research & Development: tumbled 82.75% in 2022, then soared 49.5% in 2025.
  • A 5-year view of Research & Development shows it stood at $10.9 million in 2021, then decreased by 13.37% to $9.4 million in 2022, then plummeted by 35.41% to $6.1 million in 2023, then decreased by 12.22% to $5.4 million in 2024, then soared by 45.31% to $7.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $7.8 million in Q3 2025, $6.0 million in Q2 2025, and $6.6 million in Q1 2025.